The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Alpha fetoprotein (AFP) response and efficacy outcomes in the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in advanced hepatocellular carcinoma (HCC).
 
Robin Kate Kelley
Consulting or Advisory Role - Agios (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Debiopharm Group (Inst); Genentech/Roche; Target Pharmasolutions; Target Pharmasolutions (Inst)
Research Funding - Adaptimmune (Inst); Agios (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Exelixis (Inst); Lilly (Inst); MedImmune (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Regeneron (Inst); Sanofi (Inst); Taiho Pharmaceutical (Inst); Tekmira (Inst)
 
Lorenza Rimassa
Honoraria - Abbvie; AstraZeneca
Consulting or Advisory Role - Amgen; ArQule; Baxter; Bayer; Celgene; Exelixis; Incyte; Ipsen; Italfarmaco; Lilly; Sanofi; Sirtex Medical
Travel, Accommodations, Expenses - ArQule; Ipsen
 
Baek-Yeol Ryoo
No Relationships to Disclose
 
Joong-Won Park
Honoraria - Bayer; Bristol-Myers Squibb
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; Eisai; Exelixis; Merck; Ono Pharmaceutical
 
Jean-Frédéric Blanc
Honoraria - Baxalta/Shire; Bayer Schering Pharma; Gilead Sciences
Consulting or Advisory Role - Baxalta/Shire; Bristol-Myers Squibb; Novartis; Onxeo
Travel, Accommodations, Expenses - Bayer Schering Pharma
 
Stephen Lam Chan
Honoraria - Bayer
Consulting or Advisory Role - AstraZeneca/MedImmune; MSD Oncology; Novartis
Speakers' Bureau - Amgen; Bayer; Eisai
Research Funding - Novartis; Sirtex Medical
 
Vincenzo Dadduzio
Travel, Accommodations, Expenses - Amgen; Bayer
 
Thomas Cheung Yau
Honoraria - Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb
Consulting or Advisory Role - Bristol-Myers Squibb
 
Suvajit Sen
Employment - Exelixis; Exelixis (I)
Stock and Other Ownership Interests - Exelixis; Exelixis (I)
 
David W. Markby
Employment - Exelixis
Stock and Other Ownership Interests - Exelixis
 
Rajesh Kaldate
Employment - Exelixis
Stock and Other Ownership Interests - Exelixis
Consulting or Advisory Role - Exelixis
 
Anthony B. El-Khoueiry
Honoraria - Bayer; Bristol-Myers Squibb; Merrimack; Novartis
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; CytomX Therapeutics
Speakers' Bureau - Merrimack
 
Ann-Lii Cheng
Honoraria - AstraZeneca; Bayer Yakuhin; Eisai; Genentech/Roche
Consulting or Advisory Role - AstraZeneca; Bayer Schering Pharma; Bristol-Myers Squibb; CSR Pharma; Eisai; Genentech/Roche; MSD; Novartis; Ono Pharmaceutical
 
Tim Meyer
Consulting or Advisory Role - Boehringer Ingelheim; Bristol-Myers Squibb; Novartis
Research Funding - Bayer (Inst); BTG (Inst); Ipsen (Inst)
 
Ghassan K. Abou-Alfa
Consulting or Advisory Role - 3DMedcare; Agios; Alignmed; Amgen; Antengene; Aptus Clinical; ASLAN Pharmaceuticals; Astellas Pharma; AstraZeneca; Bayer; BeiGene; BiolineRx (I); Boston Scientific; BridgeBio Pharma; Bristol-Myers Squibb; CARsgen Therapeutics; CASI Pharmaceuticals; Celgene; Celsion; Cipla; CytomX Therapeutics (I); Daiichi Sankyo; Debiopharm Group; Delcath Systems; Eisai; EMD Serono (I); Exelixis; Genoscience Pharma; Gilead Sciences (I); Halozyme; Halozyme; Hengrui Pharmaceutical; Inovio Pharmaceuticals; Ipsen; Janssen (I); Jazz Pharmaceuticals; Kyowa Hakko Kirin; LAM Therapeutics; Lilly; Loxo (I); Medimmune; Merck Serono; Minapharma; Newlink Genetics (I); Novella Clinical; Onxeo; PCI Biotech; PCI Biotech; Pfizer (I); Pharmacyclics (I); Pharmacyte Biotech (I); Pieris Pharmaceuticals (I); QED Therapeutics; RedHill Biopharma; Roche; Sanofi; SERVIER; Silenseed (I); Sillajen; Sirtex Medical; Sirtex Medical; SOBI (I); Targovax (I); Tekmira; Tekmira; twoXAR; Vicus Therapeutics (I); Yakult Pharmaceutical; Yakult Pharmaceutical; Yiviva
Research Funding - Acta Biologica (Inst); Agios (Inst); Array BioPharma (Inst); AstraZeneca (Inst); Bayer (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); CASI Pharmaceuticals (Inst); Celgene (Inst); Exelixis (Inst); Genentech (Inst); Halozyme (Inst); Incyte (Inst); Lilly (Inst); MabVax (Inst); MedImmune (Inst); Momenta Pharmaceuticals (Inst); Novartis (Inst); OncoMed (Inst); OncoQuest (Inst); Polaris (Inst); Puma Biotechnology (Inst); QED Therapeutics (Inst); QED Therapeutics (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Polaris